Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
JPRN-jRCT2031260191 CMG1A46 B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
JPRN-jRCT2031260191 clinical trial report covering CMG1A46, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623525 DIAG-723 Pulmonary Arterial Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623525 clinical trial report covering DIAG-723, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623707 B-901 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623707 clinical trial report covering B-901, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07623356 Carboplatin Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07623356 clinical trial report covering Carboplatin, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07624227 Xanomeline Tartrate/Trospium Chloride Systemic Carnitine Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07624227 clinical trial report covering Xanomeline Tartrate/Trospium Chloride, Phase 1/2, endpoints, sponsor, geography, readout timing and development
Latest Hotspot
8 min read
CTR20262182 IMM-040811 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
CTR20262182 clinical trial report covering IMM-040811, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07627698 Fludarabine Phosphate Uveal Melanoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07627698 clinical trial report covering Fludarabine Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07627971 SKY-GJB2 (Skylark Bio) Deafness, Autosomal Recessive 1A Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07627971 clinical trial report covering SKY-GJB2 (Skylark Bio), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07630363 Atorvastatin Calcium Advanced Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07630363 clinical trial report covering Atorvastatin Calcium, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07626034 SIPI6398 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07626034 clinical trial report covering SIPI6398, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600126269 LY-M003 Hepatolenticular Degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126269 clinical trial report covering LY-M003, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07629778 HL-300 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07629778 clinical trial report covering HL-300, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.